Jeffrey D. Chulay Net Worth

The estimated Net Worth of Jeffrey D. Chulay is at least $15 Thousand dollars as of 1 November 2016. Jeffrey Chulay owns over 1,000 units of Applied Genetic Technologies Corp stock worth over $7,956 and over the last 11 years Jeffrey sold AGTC stock worth over $7,050.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jeffrey Chulay AGTC stock SEC Form 4 insiders trading

Jeffrey has made over 4 trades of the Applied Genetic Technologies Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently Jeffrey sold 1,000 units of AGTC stock worth $7,050 on 1 November 2016.

The largest trade Jeffrey's ever made was exercising 4,000 units of Applied Genetic Technologies Corp stock on 11 May 2016 worth over $14,000. On average, Jeffrey trades about 889 units every 19 days since 2014. As of 1 November 2016 Jeffrey still owns at least 20,400 units of Applied Genetic Technologies Corp stock.

You can see the complete history of Jeffrey Chulay stock trades at the bottom of the page.

What's Jeffrey Chulay's mailing address?

Jeffrey's mailing address filed with the SEC is C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DR., SUITE D, ALACHUA, FL, 32615.

Insiders trading at Applied Genetic Technologies Corp

Over the last 11 years, insiders at Applied Genetic Technologies Corp have traded over $12,578,298 worth of Applied Genetic Technologies Corp stock and bought 760,946 units worth $8,946,827 . The most active insiders traders include Plc Gsk, Edward Hurwitz, and Ventures, Inc. Med Immune. On average, Applied Genetic Technologies Corp executives and independent directors trade stock every 89 days with the average trade being worth of $18,318. The most recent stock trade was executed by Stephen W Potter on 30 June 2022, trading 8,070 units of AGTC stock currently worth $6,214.

What does Applied Genetic Technologies Corp do?

Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.

Complete history of Jeffrey Chulay stock trades at Applied Genetic Technologies Corp

Applied Genetic Technologies Corp executives and stock owners

Applied Genetic Technologies Corp executives and other stock owners filed with the SEC include:

• Susan B. Washer,
  Pres, CEO & Director
• Stephen W. Potter,
  VP & Chief Bus. Officer
• Dr. Abraham Scaria Ph.D.,
  Chief Scientific Officer
• Gerald Anthony Reynolds,
  Chief Accounting Officer, Principal Accounting Officer & Treasurer
• Jonathan I. Lieber M.B.A.,
  Chief Financial Officer
• Dr. Terence R. Flotte M.D.,
  Co-Founder
• Dr. Richard Jude Samulski Ph.D.,
  Co-Founder
• Dr. William W. Hauswirth,
  Co-Founder & Member of Ophthalmology Scientific Advisory Board
• Dr. Barry J. Byrne M.D., Ph.D.,
  Co-Founder
• Dr. Nicholas Muzyczka,
  Co-Founder
• Edward Hurwitz,
  Director
• Michael H. Goldstein,
  Chief Medical Officer
• Jeffrey D. Chulay,
  V.P. & Chief Medical Officer
• Bruce Peacock,
  Director
• Ivana Magovcevic Liebisch,
  Director
• Lawrence E Bullock,
  Chief Financial Officer
• Arnold L Oronsky,
  Director
• Anne Vanlent,
  Director
• Scott Koenig,
  Director
• Mark S Shearman,
  Chief Scientific Officer
• James Rosen,
  Director
• Brian Krex,
  General Counsel
• Patrick Johan Hendrik Stich...,
  
• William A. Sullivan,
  Chief Financial Officer
• Abraham Scaria,
  Chief Scientific Officer
• Stephen W Potter,
  Chief Business Officer
• William Aliski,
  Director
• Theresa Heah,
  Chief Medical Officer
• Matthew Feinsod,
  Exec. VP, Global Strat. & Dev.
• Jill Carroll,
  Director
• Daniel L Menichella,
  V.P. & Chief Business Officer
• David R. Knop,
  Director, Process Development
• Plc Gsk,
  10% owner
• Ventures, Inc. Med Immune,
  10% owner
• Partners Viii Lp Inter West...,
  
• Samuel Wu,
  Director
• Partners Viii, L.P.Champsi ...,
  
• Susan B. Washer,
  President and CEO
• Jonathan I Lieber,
  Chief Financial Officer
• Gerald Anthony Reynolds,
  Chief Accounting Officer
• Yehia Hashad,
  Director
• Hope D Oyley Gay,
  General Counsel
• James A. Jr. Robinson,
  Director
• Susan Schneider,
  Chief Medical Officer